Biotech was one of the top sectors in the country to receive venture capital investment, according to a new report from PricewaterhouseCoopers.
Two of 2014’s top venture capital investments were in the life sciences space: $446 million into Cambridge-based Moderna Therapeutics and $320 million into the Patrick Soon-Shiong-backed Nanthealth in SoCal (a startup that, interesting, has been recently accused by whistleblower as fraudulent).
The report found that biotech investment dollars in 2014 rose 29 percent to $6 billion, but the actual number of deals dropped 4 percent to 470. The PwC report broke it down further:
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Overall, investments in 2014 in the Life Sciences sector (Biotechnology and Medical Devices combined) rose to the highest level since 2008 with $8.6 billion invested into 789 deals, a 29 percent increase in dollars but a 3 percent drop in deals compared 2013. In Q4, the Life Sciences sector captured $2.8 billion going into 202 deals, a 62 percent increase in dollars invested while deal volume remained relatively flat compared to Q3 2014. Dollars invested into Life Sciences companies accounted for 18 percent of total venture capital investments in 2014.
None of this is particularly shocking, given the general attitude of late about the biotech biz. This report’s just another point of validation.
